Emyria (EMD) Q3 2025 TU earnings summary

Executive summary

• Sustained clinical outcomes achieved in PTSD treatment, with 62.5% of patients showing significant symptom improvement and 75% reporting better quality of life three months post-treatment.

• Launched a new program for treatment-resistant depression, expanding mental health offerings.

• Opened a second Empax Centre at Perth Clinic, increasing treatment capacity by 50% and meeting third-party funding requirements.

• Leadership restructure implemented to support operational scale-up and innovation.

Financial highlights

• Net operating cash outflow for the quarter was $766,000; customer receipts totaled $359,000.

• Equity raised of $1.0 million via share issue; cash at quarter end was $1.78 million.

• Related party payments for the quarter amounted to $268,000.

Outlook and guidance

• Additional treatments at the new Empax Centre and launch of funded pilots with insurers and government health payers are expected in the coming months.

• East Coast expansion is planned, supported by rising demand and anticipated funding.